Duensing S - Search Results

1

Elevated plasma levels of interleukin-1 receptor antagonist are associated with decreased cellular BCL-2 oncoprotein expression in B-chronic lymphocytic leukemia.

Duensing S, Nasarek A, Grosse J, Ganser A, Atzpodien J. Duensing S, et al. Cancer Biother Radiopharm. 1998 Oct;13(5):383-5. doi: 10.1089/cbr.1998.13.383. Cancer Biother Radiopharm. 1998. PMID: 10851429

2

Loss of VLA-3 (CD49c/CD29) expression in two multidrug resistant Burkitt's lymphoma cell lines.

Duensing S, Duensing A, Grosse J, Atzpodien J. Duensing S, et al. Among authors: duensing a. Cancer Biother Radiopharm. 1998 Oct;13(5):369-73. doi: 10.1089/cbr.1998.13.369. Cancer Biother Radiopharm. 1998. PMID: 10851427

3

Safety, feasibility and therapeutic activity of intrapleural autologous lymphocyte conditioned medium followed by systemic recombinant interleukin-2 and interferon-alpha in a patient with malignant pleural mesothelioma.

Duensing S, Hamm H, Ganser A, Atzpodien J. Duensing S, et al. Cancer Biother Radiopharm. 1997 Jun;12(3):141-2. doi: 10.1089/cbr.1997.12.141. Cancer Biother Radiopharm. 1997. PMID: 10851459 No abstract available.

4

Dose distribution of low-dose subcutaneous recombinant interleukin-2 affects the secondary release of interferon-gamma in vivo.

Meffert M, Duensing S, Atzpodien J. Meffert M, et al. Among authors: duensing s. Cancer Biother Radiopharm. 1997 Jun;12(3):149-55. doi: 10.1089/cbr.1997.12.149. Cancer Biother Radiopharm. 1997. PMID: 10851461

5

Interleukin-12 inhibits apoptosis in chronic lymphatic leukemia (CLL) B cells.

Schuhknecht S, Duensing S, Dallmann I, Grosse J, Reitz M, Atzpodien J. Schuhknecht S, et al. Among authors: duensing s. Cancer Biother Radiopharm. 2002 Oct;17(5):495-9. doi: 10.1089/108497802760804718. Cancer Biother Radiopharm. 2002. PMID: 12470418

6

Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.

Duensing S, Hadam M, Körfer A, Schomburg A, Menzel T, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Duensing S, et al. Mol Biother. 1992 Dec;4(4):170-3. Mol Biother. 1992. PMID: 1282326

7

In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2.

Meffert M, Hanninen EL, Menzel T, Schomburg A, Duensing S, Dallmann I, Grosse J, Vocke S, Buer J, Deckert M, et al. Meffert M, et al. Among authors: duensing s. Cancer Biother. 1994 Winter;9(4):307-16. doi: 10.1089/cbr.1994.9.307. Cancer Biother. 1994. PMID: 7719378 Clinical Trial.

8

Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia.

Duensing S, Atzpodien J. Duensing S, et al. Blood. 1995 Apr 1;85(7):1978-80. Blood. 1995. PMID: 7772131 Free article. No abstract available.

9

Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma.

Lopez Hanninen E, Fenner M, Kirchner H, Deckert M, Duensing S, Menzel T, Poliwoda H, Atzpodien J. Lopez Hanninen E, et al. Among authors: duensing s. Cancer Biother. 1993 Winter;8(4):301-6. doi: 10.1089/cbr.1993.8.301. Cancer Biother. 1993. PMID: 7804371

10

Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients.

Duensing S, Grosse J, Atzpodien J. Duensing S, et al. Anticancer Res. 1995 Sep-Oct;15(5B):2331-3. Anticancer Res. 1995. PMID: 8572647

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217 results

Search Page

Filters